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Abstract
There are several classifications of Pulmonary Hypertension, one of them being Pulmonary
Arterial Hypertension (PAH). In cases in which the cause of PAH is unknown, the disease is
referred to as Idiopathic Pulmonary Arterial Hypertension (IPAH). IPAH is an extremely rare
disease, making it difficult to treat. However, over the past few decades, treatments have
expanded and improved. Treatments commonly used in clinical practice include one or more of
the following: calcium channel blockers, prostacyclin derivatives, endothelin receptor
antagonists, phosphodiesterase 5 inhibitors, guanylate cyclase stimulators, and in extreme cases
lung transplants (single or double) or heart and lung transplants. The aim of this paper is to
review the treatments and therapies available for IPAH because new information has been added
after FDA approval of new medications. This article also raises ideas of possible future clinical
trials to look at how these medications would work in a combination therapy.
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Introduction
Blood is carried from the heart to the lungs via the pulmonary arteries. Pulmonary hypertension
(PH) occurs when the blood pressure in these arteries increases. PH can be classified into five
groups, according to the World Health Organization Table 1.1 One of the groups is pulmonary
arterial hypertension. PAH is divided into subgroups based on etiology and associated treatment
options. The one of interest in this paper is idiopathic pulmonary arterial hypertension (IPAH),
which is the diagnosis when the cause cannot be determined.2 Accompanying the increased
blood pressure in the arteries, PAH is also classified by the vascular remodeling of the small
pulmonary arteries.3 Because this remodeling causes damage, gradual resistance in the
vasculature occurs often leads to right heart failure. This condition is often fatal because of its
rapid progression.

Table 1: Pulmonary Hypertension Classifications. [Based off Baliga R.S. et al. 2011, Figure 1.]
1. Pulmonary Arterial
Hypertension (PAH)

2. Pulmonary
Hypertension
with Left Heart
Disease

3. Pulmonary
Hypertension Due to
Lung Diseases and/or
Hypoxia

1.1 Idiopathic (IPAH)

2.1 Systolic
Dysfunction

3.1 Chronic Obstructive
Pulmonary Disease
(COPD)

1.2 Heritable/Familial (FPAH)
1.2.1 BMPR2
1.2.2 ALK1, Endoglin
1.2.3 Unknown
1.3 Drug and Toxin-Induced
1.4 Associated with (APAH)
1.4.1. Connective Tissue
Disorders
1.4.2. HIV infection
1.4.3. Portal Hypertension
1.4.4. Congenital Heart
disease
1.4.5 Schistasamiasis
1.4.6 Chronic Hemolytic
Anemia
1.5 Persistent Pulmonary
Hypertension of the
Newborn {PPHN}

2.2 Diastolic
Dysfunction
2.3 Valvular
Disease

3.2 Interstitial Lung
Disease
3.3 Other Pulmonary
Diseases with Mixed
Restrictive and
Obstructive Patten

4. Chronic
Thromboembolic
Pulmonary
Hypertension

5. Pulmonary
Hypertension
with Indistinct,
Multi Factorial
Mechanisms
5.1 Hematological
Disorders
5.2 Systemic
Disorders
5.3 Metabolic
Disorders
5.4 Others

3.4 Sleep Disordered
Breathing
3.5 Alveolar
Hyperventilation
Disorders
3.6 Chronic Exposure of
High Altitude
3.7 Developmental
Abnormalities

1’ Pulmonary Vena-occlusive
Disease {PVOD} and Pulmonary
Capillary Hemangiomatous {PCH}

IPAH is uncommon with an incidence of occurrence in one in every one million patients.
Clinical research opportunities are limited due to the rarity of this disease.2 This review article is
aimed to describe the available treatment options of IPAH. Current medications prescribed to
these patients include calcium channel blockers, endothelin receptor antagonists, vasodilators,
etc. The fatal outcome of IPAH can be slowed but not stopped.
Background
Diagnostic Process
The first indications of PH include fatigue, dizziness, lethargy, and dyspnea. If a patient presents
with these symptoms along with a chest pressure, chronic cough, shortness of breath, swollen
legs, the process to confirm the diagnosis and causation begins.4 The diagnostic approach is
similar within the five groups of PH. As with most diagnoses, the approach starts with a physical
exam and patient history. Further screening is performed by use of an echocardiogram, which
permits a noninvasive diagnostic method. To confirm the diagnosis the gold standard is
performance of a right heart catheterization. Both the echocardiogram and right heart
catheterization are used to measure pulmonary artery systolic pressure, but often agreement

between the two is limited. If mean right heart catheterization pressure exceeds 25 mmHg, a
diagnosis of PAH is suspected.4 Even if the pressure is determined to be low, it is not sufficient
to exclude PAH as a possible diagnosis. Other indications to consider are right arterial or
ventricular enlargement, systolic dysfunction, hypertrophy, etc.5
Other tests to confirm the diagnosis, potential causes, and determination of medication for PAH
include blood tests, blood vessel test, chest x-ray, CT scan, MRI, pulmonary function tests, and
ventilation/perfusion scan. The most common test used to evaluate the prognosis of a patient is
the 6-minute walk test, which is also often the test used in determining the efficacy, during
clinical trials, of treatments for diseases such as PAH. IPAH is a diagnosis of exclusion;
therefore if the cause cannot be determined using a variety of tests, a diagnosis of IPAH is
made.6 A simplified version of the diagnostic process, created using information from the
Cleveland Clinic, can be seen in Figure 1.7
Figure 1. Outlines stages of the diagnostic process recommended by the Cleveland clinic.7 CT,
computed tomography; ECG, electrocardiogram; HIV, human immunodeficiency
virus; PH, PAH, pulmonary arterial hypertension; TT, transthoracic; VO2, oxygen
consumption.

Molecular Pathways Involved
Currently, three pathways are implicated (Figure 2); these pathways include the endothelin (ET),
prostacyclin, and NO pathways and are targets for the current drug therapies. Figure 2 was
created using information from several others.8-11 Approved PAH therapies include ET receptor
antagonists (ERAs), prostacyclin derivatives, phosphodiesterase-5 (PDE5) inhibitors, and a
soluble guanylate cyclase (sGC) stimulator.

Figure 2: The known pathways in PAH Targeted pathways and the therapies that affect them.
Green arrows denote an increase in the intracellular concentration, red arrows indicate
blockage of a receptor, inhibition of an enzyme or a decrease in the intracellular
concentration. ET= endothelin; PDE-5 = phosphodiesterase type 5; sGC= soluble
guanylate cyclase. [Figure created using combined information from Burger, C.D et al.
2016, Zhang, Y. et al. 2012 and Humber, M. 2004]

Methods
The articles were obtained using PubMed, Medline, google, and google scholar. Clinical trials
were only included in this review article if the medication of interest was approved by the FDA
for the use of IPAH. Within the previously mentioned databases multiple phrases were searched
including: “idiopathic pulmonary arterial hypertension”, “pulmonary arterial hypertension”,
“clinical trial AND IPAH”, “treatments for idiopathic pulmonary arterial hypertension”, etc.
After finding treatment options for IPAH a google search was conducted to find FDA approved
medications; once found, PubMed, Medline, and google scholar were used to find the clinical
trials involved in these FDA approvals. Because IPAH is a rare disease, there was no restriction
applied to the date of publication.
Treatments and Therapies
Up until 1996 the gold standard of treatment for IPAH, then called primary pulmonary
hypertension, included the use of anticoagulants, calcium channel blockers (CCB), and/or the use
of oxygen therapy.12 As of 2013, all other FDA approved medications fell into three categories:
prostacyclin derivatives, endothelin receptor antagonists (ERA), phosphodiesterase 5 inhibitors
(PDE-5).3 More recently, a new drug class, guanylate cyclase stimulators, was added to

suggested treatments of IPAH. In severe cases in which medications are no longer efficacious,
transplantations of lung(s) or heart and lungs are considered.
Prostacyclin Derivatives
Prostacyclins became of interest when the medical field discovered that levels were low in PAH
patients. The discovery was made by Moncada, S. et. al. in 1976.13 Prostacyclins are
vasodilators that inhibit platelet accumulation and have anti-proliferative properties. The three
major prostacyclin derivatives used are epoprostenol, treprostinil, and iloprost. The recently
approved medication Selexipag is included in this group as well.
Epoprostenol was first approved by the FDA in 1995. It is continuously administered
intravenously using an infusion pump, due to its short half-life of only six minutes. Because of
this, infusion interruption is a concern.5 Reservoir cartridges must be changed every eight hours
(without the use of ice packs) because of the instability of the medication at room temperature.
Even with the use of ice packs it must be changed every twenty-four hours. With the short half
life and needing to change the reservoir cartridge, patients are under time constraints to get the
infusion pump up and running again. Another concern is that since a catheter is required for
continuous infusion for an extended length of time, complications such as infection of the line
and thrombosis arise. The major side effects of epoprostenol include but are not limited to:
headache, hypotension, anxiety, chest pain, nausea, and vomiting.12 Overall, epoprostenol has
been shown to have survival benefits, as well as to improve IPAH symptoms and exercise
capacity.
Almost a decade after the approval of epoprostenol, the FDA in 2002 approved treprostinil; it has
side effects similar to that of epoprostenol with the addition of dizziness and jaw pain.
Treprostinil has an extended half-life of about 4.5 hours, is chemically stable at room
temperature, and has a pH that is neutral.12 It can be administered via infusion (intravenously or
subcutaneously) or by inhaled formulations. Infusion site pain is a pragmatic association. Oral
forms of treprostinil are currently under FDA review. But, missing oral doses could be
potentially fatal and cause an abrupt return of symptoms.5,14
Three years after the approval of treprostinil, iloprost was approved by the FDA. Iloprost is an
inhaled prostacyclin derivative, but inconveniently requires 6-9 times of dosing per day.
Because of the side effects that occur with infusion therapies, inhaled versions were developed to
help alleviate those side effects. Although inhaled versions are a safer alternative, the number of
doses per day required is a challenge for patient compliance. In addition to the side effects
experienced with epoprostenol and treprostinil, iloprost side effects include but are not limited to
muscle cramps, back pain, insomnia, and some altered tastes.12
Ten years after iloprost hit the market selexipag was given the stamp of approval by the FDA in
2015. Selexipag is an oral medication that works by relaxing the muscles found in the blood
vessel walls, which causes the blood vessels to dilate, allowing for the pressure to decrease.
During the clinical trial stage it was shown to reduce hospitalization and slow progression of the
disease.15 Side effects of selexipag are similar to the above mentioned: headache, muscle pain,
diarrhea, jaw pain, nausea, vomiting, pain in extremities, (anemia), decreased appetite, and/or
rash.

These prostacyclin derivatives all have risks and benefits but the choice of mechanism of
administration varies per case.
Endothelin Receptor Antagonists (ERA)
Endothelin receptor antagonists (ERA) inhibit endothelin-1. In all forms of PAH, endothein-1 is
typically overexpressed. ET-1 is one of the most potent vasoconstrictors and induces smooth
muscle cell proliferation. ET-1 acts through receptors ET-A and ET-B. In patients with PAH,
elevated levels of ET-1 are commonly seen in the circulation and in the lungs.16
Three of the approved ERAs are bosentan, ambrisentan, and macitentan, which are all oral
therapies. They have been shown to increase exercise tolerance and avoid clinical worsening.
Because they are highly teratogenic, all ERA medications require monthly pregnancy tests in
women of child bearing potential. Potential side effects for ERAs, in addition to the side effects
mentioned for the procyclin derivatives, include: cold and flu like symptoms, urinary tract
infection, and bronchitis.5
Liver functioning tests are mandatory monthly when taking bosentan due to the risk of
hepatoxicity. Bosentan has binding affinities that are nonselective for both ET-A and ET-B. In
2001, bosentan became the first oral treatment approved by the FDA for PAH and is prescribed
to be taken twice daily.5
The approval of ambrisentan did not come until 2007. Ambrisentan is taken once daily and has
greater sensitivity for ET-A than it does for ET-B. Because of this, it is possible that it can
modify the vasoconstriction of the smooth muscle in the vasculature without the inhibitor effects
on the vasodilators.12
In 2013, macitentan was approved by the FDA. Macitentan has a greater binding affinity for ETB but can also bind to ET-A and is taken once daily. It is a derivative of bosentan with a slightly
modified structure. The reason for the modification was to improve the safety and efficacy. It
may be prescribed to be taken alone or in addition to phosphodiesterase 5 inhibitors and
prostacyclin derivatives.17,18
Phosphodiesterase 5 Inhibitors (PDE-5)
The nitric oxide (NO) pathway is down-regulated. The cyclic GMP-mediated vasodilatory
function of NO is impaired by phosphodiesterase 5 (PDE-5). PDE-5 inhibitors hinder this
impairment and allow for NO-mediated vasodilation. This mechanism is dependent on NO
availability.3,5,19 There are currently two PDE-5 inhibitors approved for the treatment of IPAH:
sildenafil and tadalafil.
The first PDE-5 inhibitor was sildenafil, which was approved by the FDA in 2009. Sildenafil
works as a vasodilator, allowing for better blood flow in the pulmonary arteries. It is also used to
treat erectile dysfunction but has been shown to improve functional class, or the extent of heart
failure, and improve exercise tolerance.5 Sildenafil is generally prescribed to be taken three times
daily, unless dealing with a more severe case of PAH. Side effects of sildenafil include but are
not limited to memory problems, back pain, loss of hearing, ringing in the ears, and/or dizziness.
Physicians should be aware that when sildenafil is taken along with the ERA bosentan, the two
drugs co-interact and sildenafil levels decrease while bosentan levels increase (putting patient at
further risk for hepatoxicity).14

It wasn’t until eight years later that the second PDE-5 inhibitor, tadalafil, was approved by the
FDA. Tadalafil also improves exercise tolerance and slows disease progression.5 Side effects for
tadalafil include upper respiratory tract infection, back pain, myalgia, cough, and/or nasal
congestion. It was approved by the FDA for use starting at 40 mg.12,20
Guanylate Cyclase Stimulators
Extensive literature research demonstrated that the only reported FDA approved guanylate
cyclase stimulator for IPAH is riociguat, approved in 2013. Riociguat side effects include
gastroesophageal reflux disease, and the combination of side effects listed for the prostacyclin
derivatives. The mechanisms of riociguat work by relaxing the arteries, causing the blood
pressure to decrease and blood flow to increase. Riociguat is taken three times daily and was
shown to have a positive effect on improving exercise tolerance. Physicians must be aware that
female patients must be enrolled in Adempas Risk Evaluation and Mitigation Strategy (REMS)
program to be able to receive the drug. This program sets contraception guidelines as well as
regular pregnancy testing for all women taking riociguat. The reason for this is that riociguat can
harm a developing fetus; therefore, women in child-bearing years must take certain precautions
that are outlined in the program.21,22
Table 2 summarizes the updated medications and the pathways that they are involved in; it was
created based on information in Table 1 from Ruiz, G. et. al.23
Table 2. Medication and the mechanism of action for PAH.

Transplantations
If medications do not work or lose efficacy, the remaining treatment option is to perform a lung
or heart and lung transplant. The possible transplant types include: single lung transplant, double
lung transplant, or heart and lung transplant. The median survival rate after lung transplant is 4.9
years and the median survival rate after both heart and lung transplant is 5 years. Most deaths
after transplantation occur within the first year.24 Consideration of transplant is recommended
early in disease progression in order to be evaluated for the transplant list and allow adequate

survival time until a transplant becomes available.12 Limitations of transplantation include the
possibility of rejection, limited number of organs that become available, and also finding the
perfect match.
Combination Treatments and Therapies
Research considering the use of a combination of treatment and therapies has been limited and
mostly observational. One clinical trial in 2008 showed promising results for IPAH using the
combination treatment of prostacyclin derivatives and PDE inhibitors, specifically epoprostenol
and sildenafil. This was a 2-arm treatment group; one arm was taking only the maximum amount
of epoprostenol while the treatment group (combination group) was taking both epoprostenol and
sildenafil. The results included a statistically significant 6-minute walk distance increase and a
greater decrease in pulmonary arterial pressure in the combination group.25
A more recent clinical trial conducted a 3-arm clinical trial comparing ambrisentant vs. tadalfil
vs. the combination of ambrisentan and tadalfil. The results of this study were published in 2015
and showed an improvement in 6-minute walk distance but there were higher numbers of adverse
events. Some of the adverse events included anemia, nasal congestion, headache and peripheral
edema.26 Although there are no clinical trials to highly support the use of combination medicines
and therapies, physicians often prescribe blood thinners, diuretics, digoxin, and oxygen therapy
in addition to the single agent treatments listed above.6 At the physician’s discretion, a
combination of the single agents may be prescribed. This may happen if a patient fails to
respond to the first therapy and completely changing to a single agent could result in regression
of current clinical status.12
Discussion
There are limitations in diagnosing and managing the disease. Because of the disease incidence
being low and the signs and symptoms being nonspecific, diagnosis can be a challenge. When a
patient who presents with symptoms that are nonspecific, such as dyspnea or dizziness, and other
diseases have been ruled out, PAH should be considered as a diagnosis by the physician.
Echocardiography, as mentioned before, is a tool used in the diagnosis process. Overreliance on
this test sometimes results in misclassification and management measures of the disease. To
help in selecting the right therapy and treatment of the disease, a patient should undergo right
heart catheterization to get an accurate measure of the pressures and assess right ventricular
function.
Education of both public and healthcare providers could help increase awareness of the disease.
This education could help result in consideration of this disease more often when
cardiorespiratory disorders cannot be attributed to the patient symptoms. With consideration of
this disease more often, early referral is recommended of patients with suggestive symptoms or
abnormal echocardiography, especially high risk population, to specialists in this field to confirm
the diagnosis through right heart catheterization. Early referral could result in the patient getting
the care they need quicker, leading to management of the disease which could result in better
quality of life. The efficacy of these medications overall seem to improve quality of life,
however, no cure has yet to be found.

Conclusion
Over the past couple decades, the availability and quality of treatments and therapies have
improved for IPAH. Although treatments and therapies have improved disease progression and
survival rate, there is still no definite cure. Future research should target new classes of drugs in
the effort to find a cure, as well as to explore the effectiveness of combination of treatments and
therapies. Currently, there is no clear assertion as to which treatment is better; physicians should
evaluate on a case-by- case basis. This review aimed to include all current FDA approved
treatments and therapies for idiopathic pulmonary arterial hypertension, achieved through
extensive literature research and confirmations from fda.gov.
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